TAXUS Libertē Post Approval Study

Completed · Has a placebo group

Conditions studied: Coronary Artery Disease

In brief

The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen. This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Study).

Key facts

Study ID
NCT00997503
Run by
Boston Scientific Corporation
People needed
4199
Starts
2009-12-01
Expected to finish
2015-07-01
Last updated by the study team
2015-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.